Through the Diflucan® Partnership Program, Pfizer's antifungal medicine Diflucan® (fluconazole) is made available free of charge for the treatment of cryptococcal meningitis and esophageal candidiasis, two opportunistic infections associated with HIV/AIDS, to governments and nongovernmental organizations in developing countries. Countries with HIV/AIDS prevalence greater than 1 percent are given priority.
Governments and nongovernmental organizations may apply to the Diflucan® Partnership Program by submitting an application. See a list of eligible countries in the Diflucan® Partnership Program.
Diflucan® for donation is available in the following dosage forms: 200 mg tablets (pink in color), 200 mg intravenous vials and 50 mg/5 ml powder for oral suspension for pediatric use. The Diflucan® Partnership Program also provides information for health professionals on the diagnosis and treatment of cryptococcal meningitis and esophageal candidiasis.
The prescription and use of Diflucan® requires the donated product to be registered in the country of use. If these dosage forms and indications of Diflucan® are not registered, the applying organization must secure a special import license, waiver, or other documentation required by the government of the country to receive the donation.
The Diflucan® Partnership offers Diflucan® free of charge and will cover the shipping costs up to the point of entry in the country. The recipient is responsible for all other charges, including costs of handling, taxes and duties, and distribution in the country.
About the Partners
Pfizer Inc, a worldwide biopharmaceutical company, manufactures Diflucan® and donates it to Direct Relief International. A nonprofit medical aid organization, Direct Relief International processes the applications, maintains databases, and monitors re-ordering for the applicant organizations.
Note: Pages will open in a new browser window. External sites are not endorsed by the Diflucan® Partnership Program.